News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,366 Results
Type
Article (44838)
Company Profile (329)
Press Release (679198)
Multimedia
Podcasts (99)
Webinars (15)
Section
Business (208119)
Career Advice (2028)
Deals (36000)
Drug Delivery (111)
Drug Development (84125)
Employer Resources (174)
FDA (16777)
Job Trends (15155)
News (353158)
Policy (33365)
Tag
Academia (2688)
Academic (1)
Accelerated approval (14)
Adcomms (29)
Allergies (101)
Alliances (50934)
ALS (117)
Alzheimer's disease (1553)
Antibody-drug conjugate (ADC) (178)
Approvals (16754)
Artificial intelligence (335)
Autoimmune disease (34)
Automation (20)
Bankruptcy (366)
Best Places to Work (11852)
BIOSECURE Act (22)
Biosimilars (130)
Biotechnology (236)
Bladder cancer (103)
Brain cancer (40)
Breast cancer (401)
Cancer (3122)
Cardiovascular disease (243)
Career advice (1697)
Career pathing (30)
CAR-T (214)
CDC (34)
Cell therapy (580)
Cervical cancer (24)
Clinical research (69249)
Collaboration (1126)
Company closure (3)
Compensation (738)
Complete response letters (35)
COVID-19 (2718)
CRISPR (69)
C-suite (377)
Cystic fibrosis (123)
Data (3224)
Decentralized trials (2)
Denatured (27)
Depression (73)
Diabetes (369)
Diagnostics (6566)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (156)
Drug pricing (135)
Drug shortages (31)
Duchenne muscular dystrophy (160)
Earnings (88685)
Editorial (47)
Employer branding (21)
Employer resources (150)
Events (116985)
Executive appointments (887)
FDA (18595)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (995)
Gene editing (149)
Generative AI (26)
Gene therapy (457)
GLP-1 (867)
Government (4646)
Grass and pollen (5)
Guidances (220)
Healthcare (19353)
HIV (43)
Huntington's disease (31)
IgA nephropathy (40)
Immunology and inflammation (174)
Immuno-oncology (11)
Indications (42)
Infectious disease (2902)
Inflammatory bowel disease (159)
Inflation Reduction Act (10)
Influenza (69)
Intellectual property (128)
Interviews (314)
IPO (16837)
IRA (48)
Job creations (3702)
Job search strategy (1436)
Kidney cancer (14)
Labor market (55)
Layoffs (539)
Leadership (20)
Legal (8036)
Liver cancer (82)
Longevity (12)
Lung cancer (438)
Lymphoma (224)
Machine learning (12)
Management (58)
Manufacturing (442)
MASH (101)
Medical device (13729)
Medtech (13736)
Mergers & acquisitions (19921)
Metabolic disorders (923)
Multiple sclerosis (101)
NASH (18)
Neurodegenerative disease (154)
Neuropsychiatric disorders (40)
Neuroscience (2304)
NextGen: Class of 2025 (6722)
Non-profit (4590)
Now hiring (50)
Obesity (463)
Opinion (237)
Ovarian cancer (106)
Pain (124)
Pancreatic cancer (129)
Parkinson's disease (199)
Partnered (22)
Patents (329)
Patient recruitment (184)
Peanut (52)
People (58863)
Pharmaceutical (76)
Pharmacy benefit managers (21)
Phase I (21605)
Phase II (30451)
Phase III (22725)
Pipeline (1762)
Policy (224)
Postmarket research (2723)
Preclinical (9233)
Press Release (69)
Prostate cancer (154)
Psychedelics (45)
Radiopharmaceuticals (272)
Rare diseases (527)
Real estate (6024)
Recruiting (68)
Regulatory (23416)
Reports (50)
Research institute (2436)
Resumes & cover letters (353)
Rett syndrome (10)
RNA editing (11)
RSV (54)
Schizophrenia (97)
Series A (166)
Series B (118)
Service/supplier (12)
Sickle cell disease (68)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (34)
Startups (3725)
State (2)
Stomach cancer (17)
Supply chain (78)
Tariffs (63)
The Weekly (70)
Vaccines (836)
Venture capital (57)
Weight loss (296)
Women's health (49)
Worklife (17)
Date
Today (21)
Last 7 days (552)
Last 30 days (1762)
Last 365 days (31817)
2025 (18572)
2024 (36308)
2023 (41053)
2022 (52297)
2021 (56827)
2020 (55098)
2019 (47636)
2018 (35957)
2017 (33034)
2016 (32438)
2015 (38445)
2014 (32164)
2013 (27177)
2012 (29331)
2011 (30045)
2010 (28196)
Location
Africa (752)
Alabama (63)
Alaska (7)
Arizona (249)
Arkansas (13)
Asia (39674)
Australia (6553)
California (7802)
Canada (2451)
China (725)
Colorado (330)
Connecticut (335)
Delaware (203)
Europe (87425)
Florida (1186)
Georgia (267)
Hawaii (2)
Idaho (61)
Illinois (672)
India (29)
Indiana (376)
Iowa (18)
Japan (245)
Kansas (113)
Kentucky (31)
Louisiana (15)
Maine (64)
Maryland (1068)
Massachusetts (5907)
Michigan (250)
Minnesota (472)
Mississippi (4)
Missouri (104)
Montana (29)
Nebraska (25)
Nevada (85)
New Hampshire (72)
New Jersey (2175)
New Mexico (30)
New York (2186)
North Carolina (1174)
North Dakota (10)
Northern California (3440)
Ohio (246)
Oklahoma (17)
Oregon (35)
Pennsylvania (1694)
Puerto Rico (17)
Rhode Island (37)
South America (1123)
South Carolina (35)
South Dakota (1)
Southern California (2918)
Tennessee (130)
Texas (1193)
United States (29073)
Utah (226)
Virginia (194)
Washington D.C. (75)
Washington State (660)
West Virginia (4)
Wisconsin (71)
724,366 Results for "biorestorative therapies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York.
June 4, 2024
·
3 min read
Press Releases
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
May 14, 2025
·
8 min read
Press Releases
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
March 28, 2025
·
7 min read
Press Releases
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
May 8, 2025
·
4 min read
Press Releases
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
June 16, 2025
·
6 min read
Business
BioRestorative Therapies Provides First Quarter 2024 Business Update
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business.
May 14, 2024
·
6 min read
Pharm Country
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
BioRestorative Therapies, Inc. reported that it has had substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a license of BioRestorative’s allogeneic, off-the-shelf ThermoStem® metabolic intellectual property.
June 13, 2024
·
5 min read
Press Releases
BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025
March 20, 2025
·
4 min read
Press Releases
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
May 7, 2025
·
5 min read
Press Releases
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
June 9, 2025
·
3 min read
1 of 72,437
Next
